ArticleMaterials today. Bio2026
Electroacupuncture synergizes with anti-ferroptosis bioelectrical niche remodeling to promote spinal cord regeneration.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe spinal cord injury (SCI) frequently causes persistent neurological deficits, and its repair is constrained by multiple pathological factors including deterioration of the microenvironment following secondary injury, massive neuronal loss, interruption of electrical signal conduction, and insufficient endogenous regenerative capacity. Although electroacupuncture (EA) participates in the rehabilitation of SCI by regulating inflammatory responses and promoting the secretion of neurotrophic factors, standalone EA therapy can hardly fully reverse oxidative stress, ferroptosis and neural circuit destruction following severe SCI. Accordingly, this study constructs a conductive anti-ferroptosis hydrogel system (HBP@BMSCs), which utilizes dopamine-grafted hyaluronic acid (HADA) as the bionic matrix, baicalin-polypyrrole (BA-PPy) as the functional component, and is loaded with bone marrow mesenchymal stem cells (BMSCs). This hydrogel system is combined with EA for the repair of severe SCI. The results demonstrate that the HBP hydrogel exhibits favorable cytocompatibility, which can support the survival of BMSCs and maintain their typical mesenchymal stem cell phenotype. In vitro experiments demonstrate that HBP hydrogel effectively alleviates TBHP-induced oxidative stress injury and Erastin-induced ferroptosis-related injury, and exerts a protective effect on BMSCs and PC12 cells. In vivo experiments further confirmed that the combination therapy of HBP@BMSCs with EA significantly downregulated the expression levels of 4HNE, COX2, NOX2, FTH, FTL and TFR after SCI, and restored the expression levels of XCT, GPX4, SOD1 and FPN, thereby alleviating ROS accumulation, lipid peroxidation, iron overload and ferroptosis. With the alleviation of oxidative stress and ferroptosis-related secondary damage, the combination therapy further downregulates the expression of Bax and C-caspase3, upregulates Bcl-2 levels, and significantly inhibits neuronal apoptosis. In addition, the BA-PPy conductive network can synergize with EA to enhance electrical stimulation conduction, upregulate NGF/NGFR and BDNF neurotrophic signaling pathways, and promote the neural lineage differentiation of BMSCs, axon regeneration, corticospinal tract (CST) remodeling, and the recovery of motor function. In conclusion, HBP@BMSCs combined with EA exerts multiple synergistic effects including microenvironment remodeling, anti-ferroptosis protection, stem cell delivery and electroactive neural regeneration, providing a comprehensive therapeutic strategy with translational potential for severe SCI repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.